WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of 21.19 billion. The enterprise value is 20.73 billion.
| Market Cap | 21.19B |
| Enterprise Value | 20.73B |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.55% |
| Shares Change (QoQ) | -0.30% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | 37.19% |
| Float | 3.73B |
Valuation Ratios
The trailing PE ratio is 36.18 and the forward PE ratio is 27.35.
| PE Ratio | 36.18 |
| Forward PE | 27.35 |
| PS Ratio | 7.57 |
| PB Ratio | 3.09 |
| P/TBV Ratio | 3.53 |
| P/FCF Ratio | 86.29 |
| P/OCF Ratio | 26.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.24, with an EV/FCF ratio of 84.39.
| EV / Earnings | 35.38 |
| EV / Sales | 7.37 |
| EV / EBITDA | 21.24 |
| EV / EBIT | 26.92 |
| EV / FCF | 84.39 |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.88 |
| Quick Ratio | 2.40 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | 2.90 |
| Interest Coverage | 31.72 |
Financial Efficiency
Return on equity (ROE) is 10.50% and return on invested capital (ROIC) is 10.55%.
| Return on Equity (ROE) | 10.50% |
| Return on Assets (ROA) | 5.89% |
| Return on Invested Capital (ROIC) | 10.55% |
| Return on Capital Employed (ROCE) | 10.57% |
| Weighted Average Cost of Capital (WACC) | 6.18% |
| Revenue Per Employee | 223,025 |
| Profits Per Employee | 46,667 |
| Employee Count | 12,552 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 6.36 |
Taxes
In the past 12 months, WuXi Biologics has paid 172.04 million in taxes.
| Income Tax | 172.04M |
| Effective Tax Rate | 20.03% |
Stock Price Statistics
The stock price has increased by +88.07% in the last 52 weeks. The beta is 0.37, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +88.07% |
| 50-Day Moving Average | 9.00 |
| 200-Day Moving Average | 8.18 |
| Relative Strength Index (RSI) | 64.76 |
| Average Volume (20 Days) | 56,262 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of 2.80 billion and earned 585.76 million in profits. Earnings per share was 0.14.
| Revenue | 2.80B |
| Gross Profit | 1.19B |
| Operating Income | 766.36M |
| Pretax Income | 859.06M |
| Net Income | 585.76M |
| EBITDA | 949.90M |
| EBIT | 766.36M |
| Earnings Per Share (EPS) | 0.14 |
Balance Sheet
The company has 1.75 billion in cash and 712.90 million in debt, with a net cash position of 1.04 billion.
| Cash & Cash Equivalents | 1.75B |
| Total Debt | 712.90M |
| Net Cash | 1.04B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.85B |
| Book Value Per Share | 1.54 |
| Working Capital | 2.23B |
Cash Flow
In the last 12 months, operating cash flow was 798.72 million and capital expenditures -553.15 million, giving a free cash flow of 245.57 million.
| Operating Cash Flow | 798.72M |
| Capital Expenditures | -553.15M |
| Free Cash Flow | 245.57M |
| FCF Per Share | n/a |
Margins
Gross margin is 42.65%, with operating and profit margins of 27.38% and 20.92%.
| Gross Margin | 42.65% |
| Operating Margin | 27.38% |
| Pretax Margin | 30.69% |
| Profit Margin | 20.92% |
| EBITDA Margin | 33.93% |
| EBIT Margin | 27.38% |
| FCF Margin | 8.77% |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.55% |
| Shareholder Yield | 2.55% |
| Earnings Yield | 2.76% |
| FCF Yield | 1.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 10, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Dec 10, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
WuXi Biologics has an Altman Z-Score of 5.11 and a Piotroski F-Score of 8.
| Altman Z-Score | 5.11 |
| Piotroski F-Score | 8 |